ClinicalTrials.gg
Active, not recruitingNCT06098482VALDE-MUUpdated Oct 22, 2026

An Investigation to Validate Speech Perception Assessment for Adult Cochlear Recipients Using a Mobile Research App

An interventional study of Mobile Research App (MRA) and SOC/validated delivery of the speech perception test material in Hearing Loss, sponsored by Cochlear. Active, not recruiting at 4 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Cochlear · Not applicable, Interventional, and Basic science

Updated Oct 22, 2026Now Active, not recruiting1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
46
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 50 studies in Hearing Loss by Cochlear — 5 open to participants now, 12 under way, none of them phase 3. Hearing Loss · Cochlear.

Planned enrollment
16th of 43
46 · median 32
Started
2024
with 5 others
No phase
43 of 50
4 open now
Primary completion
2027-05
later than 5 of 11 live
Registered
38th of 50
by date

Among the 50 studies in Hearing Loss by Cochlear, this one is the 16th largest by planned enrollment of the 43 interventional ones that give a count, is one of 6 that started in 2024, is one of 43 with no phase, reaches primary completion later than 5 of the 11 other live ones, and was the 38th registered.

Hearing Loss

797 studies on the registry are indexed under Hearing Loss; 195 are open to participants now.

Browse Hearing Loss studies →

Open to participants now

5 of the 50 studies in Hearing Loss by Cochlear are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 125 Hearing Loss studies recruiting now, 60 (48%) set no upper age limit and 43 (34%) stop at 75 or younger; 47 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies in Hearing Loss by Cochlear, or all of them as a file.
02

Study summary

The study is a feasibility, prospective, repeated-measures, multi-country, multi-centre, study of the Mobile Research App to measure and validate speech perception endpoints in adult cochlear implant recipients.

03

Conditions studied

  • Hearing Loss

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults 18 years of age or older.
  • Uses a hearing device or devices (hearing aid/s and/or cochlear implant/s).
  • Fluent speaker in the language used to assess clinical performance as judged by the investigator.
  • Willing and able to provide written .

Exclusion criteria

Exclusion Criteria:

  • Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator.
  • Investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as a spouse, parent, child, or sibling.
  • Cochlear employees or employees of Contract Research Organisations or contractors engaged by Cochlear for the purposes of this investigation.
  • Currently participating, or participated within the last 30 days, in another interventional clinical investigation/trial involving an drug or device (unless the other investigation was/is a Cochlear sponsored investigation and determined by the investigator or Sponsor to not impact this investigation).
  • Women who are pregnant.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
46 participants (estimated)

Study arms

  • Experimental
    Delivery of speech perception materials in-clinic using the Mobile Research App (MRA)

    Cochlear implant recipients will participate in this arm (sub-investigation AI5841A).

    Device: Mobile Research App (MRA) · Other: SOC/validated delivery of the speech perception test material

  • Experimental
    Delivery of speech perception materials in-clinic and at home using the Mobile Research App (MRA)

    Cochlear implant and hearing aid recipients will participate in this arm (sub-investigation AI5841B).

    Device: Mobile Research App (MRA) · Other: SOC/validated delivery of the speech perception test material

Interventions

  • DeviceMobile Research App (MRA)

    The MRA (research tool) is a platform used for the delivery of speech perception material in-clinic outside the sound booth or in the home of the hearing-impaired recipients. The MRA speech testing module delivers speech material via streaming to the single implanted ears of cochlear implant recipients. The recipient listens to the speech material and responds with what was heard via the app. Speech is streamed via Bluetooth from the iOS device to the sound processor of the CI-recipient.

  • OtherSOC/validated delivery of the speech perception test material

    This involves the delivery of speech perception test material in the sound booth in a clinic.

06

What researchers measure

Primary outcomes

  1. Percent correct performance for the test and retest runs of speech perception ability

    To determine if test-retest reliability with a correlation greater than or equal to 0.8 can be achieved for speech perception ability measured on the MRA outside the sound booth, percent correct performance for the test and retest runs of the speech perception ability will be compared. Scoring: Percentage correct Range: 0-100%, higher scores equal better performance

    Time frame: 1 day - immediately post screening.

07

Study locations

4 sites
  • Denver Research and Technology Labs
    Lone Tree, Colorado 80124, United States
  • HEARnet Clinical Studies
    Melbourne, Victoria 3053, Australia
  • European Institute for Otorhinolaryngology (EIORL) ENT department Sint-Augustinus Antwerp
    Antwerp, Antwerp 2610, Belgium
  • Hoorzorg van Looveren
    Wommelgem, Antwerp 2160, Belgium
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for May 2027, 38 months after the start.

Of 126 industry-sponsored interventional studies with no phase under Hearing Loss, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 15. This study's planned 38 months is above that.

Counting every sponsor, half of 323 studies reached it within 19 months; a quarter within 5 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2023
First posted
Oct 24, 2023
StartActual
Feb 5, 2024
Primary completionEst.
May 2, 2027
CompletionEst.
May 2, 2027
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 22, 2026
Sites
1 site added, 1 site removed
Show site
  • European Institute for Otorhinolaryngology (EIORL) ENT department Sint-Augustinus Antwerp · Antwerp, Belgium
Show 1 removed
  • European Institute for Otorhinolaryngology (EIORL) ENT department Sint-Augustinus Antwerp · Antwerp, Belgium
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Recruiting→Active, not recruiting
    1 site added, 1 site removed
    Show site
    • European Institute for Otorhinolaryngology (EIORL) ENT department Sint-Augustinus Antwerp · Antwerp, Belgium
    Show 1 removed
    • European Institute for Otorhinolaryngology (EIORL) ENT department Sint-Augustinus Antwerp · Antwerp, Belgium
    + 4 other changes: verification date, oversight details, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06098482
Lead sponsor
Cochlear
Responsible party
Sponsor
First posted
Oct 24, 2023
Start date
Feb 5, 2024
Primary completion
May 2, 2027 (estimated)
Completion
May 2, 2027 (estimated)
Last update
Oct 22, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion